ETOPOSIDE - Generic Drug Details

What are the generic drug sources for etoposide and what is the scope of patent protection?

Etoposide is the generic ingredient in four branded drugs marketed by Mylan, Strides Pharma, Accord Hlthcare, Dash Pharms, Dash Pharms Natco, Fresenius Kabi Usa, Hikma, Hospira, Meitheal, Pharmachemie Bv, Pierre Fabre, Teva Parenteral, Teva Pharms Usa, Watson Labs, Watson Labs Inc, Corden Pharma, Bristol Myers Squibb, and Cheplapharm, and is included in twenty NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for etoposide. Five suppliers are listed for this compound.

Summary for ETOPOSIDE

US Patents:	0
Tradenames:	4
Applicants:	18
NDAs:	20
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	1,601
Patent Applications:	4,050
Drug Prices:	Drug price trends for ETOPOSIDE
What excipients (inactive ingredients) are in ETOPOSIDE?	ETOPOSIDE excipients list
DailyMed Link:	ETOPOSIDE at DailyMed

See drug prices for ETOPOSIDE

Recent Clinical Trials for ETOPOSIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Genentech, Inc.	Phase 1/Phase 2
Vanderbilt-Ingram Cancer Center	Phase 1/Phase 2
Vanderbilt-Ingram Cancer Center	Phase 2

See all ETOPOSIDE clinical trials

Pharmacology for ETOPOSIDE

Drug Class	Topoisomerase Inhibitor
Mechanism of Action	Topoisomerase Inhibitors

Medical Subject Heading (MeSH) Categories for ETOPOSIDE

Antineoplastic Agents, Phytogenic

Topoisomerase II Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for ETOPOSIDE

L01CB	Podophyllotoxin derivatives
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ETOPOSIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	ETOPOSIDE	etoposide	INJECTABLE;INJECTION	074284-001	Feb 10, 1994		DISCN	No	No
Teva Parenteral	ETOPOSIDE	etoposide	INJECTABLE;INJECTION	074510-001	Jun 29, 1995		DISCN	No	No
Accord Hlthcare	ETOPOSIDE	etoposide	INJECTABLE;INJECTION	074513-001	Mar 14, 1996	AP	RX	No	No
Bristol Myers Squibb	ETOPOPHOS PRESERVATIVE FREE	etoposide phosphate	INJECTABLE;INJECTION	020906-001	Feb 27, 1998		DISCN	No	No

Expired US Patents for ETOPOSIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-001	Dec 30, 1986
Corden Pharma	VEPESID	etoposide	INJECTABLE;INJECTION	018768-001	Nov 10, 1983
Strides Pharma	VEPESID	etoposide	CAPSULE;ORAL	019557-002	Dec 30, 1986

ETOPOSIDE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Etoposide

Introduction to Etoposide

Etoposide is a chemotherapeutic agent widely used in the treatment of various types of cancer, including small cell lung cancer, testicular cancer, and certain types of leukemia and lymphoma. The drug's market dynamics are influenced by several key factors, including the prevalence of cancer, demographic changes, and advancements in healthcare.

Market Size and Growth

The global Etoposide market has been valued at USD 715.62 million in 2023 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 5.8% from 2024 to 2030, reaching approximately USD 1.061 billion by the end of the forecast period[1][4].

Drivers of Market Growth

Increasing Prevalence of Cancer

One of the primary drivers of the Etoposide market is the growing prevalence of cancer, particularly prostate cancer, which is the second most common type of cancer among men. According to Globocan 2021 data, prostate cancer accounted for 1.4 million cases, or 7.2% of all malignant tumors globally. The aging population, which is more prone to prostate cancer, is expected to further drive the market growth[1].

Demographic Factors

The world's aging population is a significant demographic factor contributing to the growth of the Etoposide market. Prostate cancer is more frequent among senior citizens, and as the global population ages, the demand for Etoposide is likely to increase[1].

Advances in Healthcare and Research

Continuous research and development in the field of oncology are enhancing the effectiveness and applicability of Etoposide. Companies and academic institutions are investing heavily in this area, leading to improved treatment outcomes and broader usage of the drug[1].

Market Segmentation

By Application

The Etoposide market is segmented by application, with key segments including small cell lung cancer, testicular cancer, and other types of cancer such as leukemia and lymphoma. The small cell lung cancer segment is expected to grow at a CAGR of 3.8% during the forecast period[1].

By Form

Etoposide is available in various forms, including injectable solutions and oral formulations. The market is segmented based on these forms, with each having different growth trajectories and market shares[1][4].

By Region

Geographically, the Etoposide market is dominated by North America, particularly the United States and Canada, due to the high prevalence of prostate cancer and other cancers in these regions. Europe and the Asia-Pacific region are also significant markets, driven by increasing cancer incidence and improved healthcare infrastructure[1][4].

Financial Assistance and Access

Financial Assistance Programs

To make Etoposide more accessible, pharmaceutical companies like Pfizer offer financial assistance programs. For example, Pfizer Oncology Together provides co-pay savings programs where eligible, commercially insured patients may pay as little as $0 per month for certain oral medicines or per treatment for injectable medicines. These programs can offer savings up to $9,450 per product annually for oral medicines and $10,000 to $25,000 for injectable medicines[2].

Patient Assistance Programs

For patients who are uninsured or underinsured, programs like the Pfizer Patient Assistance Program can provide free medicines. These programs help in reducing the financial burden on patients and ensure that they have access to necessary treatments[2].

Challenges and Restraints

High Cost of Cancer Medications

One of the significant restraints for the Etoposide market is the high cost of cancer medications. This can limit access to the drug, especially in regions with limited healthcare resources and insurance coverage[1].

Regulatory and Competitive Pressures

The market also faces regulatory and competitive pressures. The approval process for new drugs and the presence of generic alternatives can impact the market share of branded Etoposide products. Additionally, changes in healthcare policies and reimbursement structures can affect the market dynamics[1].

Competitive Landscape

The Etoposide market is characterized by a competitive landscape with several key players. These companies are investing in research and development to improve the efficacy and safety of Etoposide. Market leaders, followers, and new entrants are analyzed in comprehensive market reports to provide a clear understanding of the competitive scenario[1].

Regional Insights

North America

North America, particularly the United States and Canada, is expected to hold a considerable market share due to the rising frequency of prostate cancer and other cancers. The US Food and Drug Administration's efforts to expedite drug approvals also contribute to the growth in this region[1].

Europe and Asia-Pacific

Europe and the Asia-Pacific region are also significant markets. In Europe, the market is driven by the prevalence of cancer and the presence of advanced healthcare infrastructure. In the Asia-Pacific region, emerging markets and increasing healthcare spending are key drivers[1][4].

Future Outlook

The future outlook for the Etoposide market is positive, driven by the increasing prevalence of cancer, demographic changes, and advancements in healthcare. Ongoing research and development are expected to enhance the drug's effectiveness and broaden its applicability.

Statistics and Projections

• Market Size: Expected to reach USD 1.061 billion by 2030[1].
• CAGR: 5.8% from 2024 to 2030[1].
• Regional Growth: North America to hold a significant market share, followed by Europe and the Asia-Pacific region[1][4].

Key Takeaways

• The Etoposide market is driven by the growing prevalence of cancer, particularly prostate cancer.
• Demographic factors such as the aging population contribute to market growth.
• Financial assistance programs and patient assistance initiatives help in making the drug more accessible.
• The market faces challenges such as high medication costs and regulatory pressures.
• North America is expected to dominate the market, with significant contributions from Europe and the Asia-Pacific region.

FAQs

What is the primary driver of the Etoposide market?

The primary driver of the Etoposide market is the growing prevalence of prostate cancer and other types of cancer.

Which region is expected to hold a considerable market share for Etoposide?

North America, particularly the United States and Canada, is expected to hold a considerable market share.

What are the restraints for new market entrants in the Etoposide market?

The high cost of cancer medications is a major restraint for new market entrants.

How does financial assistance impact the accessibility of Etoposide?

Financial assistance programs, such as those offered by Pfizer, help reduce the financial burden on patients by providing co-pay savings and free medicines for eligible patients.

What is the projected market size and growth rate of the Etoposide market?

The Etoposide market is expected to grow at a CAGR of 5.8% from 2024 to 2030, reaching nearly USD 1.061 billion by 2030.

Sources

1. Maximize Market Research: Etoposide Market - Region and Forecast (2024-2030)
2. Pfizer Oncology Together: Financial Assistance
3. Merck Group: BAML Global HC Conference London 2019
4. Market Research Intellect: Global Etoposide Market Size, Share, Industry Growth, Forecast, 2031